

Questionnaire of health impact of coronavirus on the care of cancer patients in the Hematology Department

Implementation of Specific Action Plan

Date of first test	____/____/____
Triage: Clean and dirty circuits	Yes / No
On-site PCR (Suspected cases)	Yes / No Date____/____/____
Change from in-person to telephone visit	Yes / No
In-person care maintained in department?	Yes / No

Specific treatment guidelines

Department	Yes / No
National guidelines	Yes / No
International guidelines	Yes / No
Other	Yes / No

COVID-positive patients in department

Total patients	_____
Confirmed patients	_____
Admitted patients	_____
Patient deaths	_____

Number of tests performed

PCR	_____
Serology	_____

Health Impact of Coronavirus on the Care of Cancer Patients

	Year	March	April	May	June
Aspirated bone marrow	2019				
	2020				
Bone marrow biopsies	2019				
	2020				
Cytometries	2019				
	2020				
Genetic testing of neoplasms	2019				
	2020				

Consultations

		Year	March	April	May	June
New consultations		2019				
		2020				
Successive consultations	Telephone	2019				
		2020				
	In-person	2019				
		2020				

Systemic treatments

	Year	March	April	May	June
Patients treated in day hospital	2019				
	2020				
Treatments in Hematology department	2019				
	2020				
Maintenance treatments	2019				
	2020				
Patients treated with chemotherapy	2019				
	2020				
Patients with GCSF	2019				
	2020				

Hematopoietic Stem Cell Transplant Patients

	Year	March	April	May	June
Autologous	2019				
	2020				
Allogenic	2019				
	2020				

Clinical research (Clinical trials)

	Year	March	April	May	June
Clinical trials recruiting	2019				
	2020				
Interrupted due to COVID-19*	2020				
Abandoned due to COVID-19**	2020				
Patients in screening	2019				
	2020				
Patients included	2019				
	2020				

*Clinical trial postponed for a time but not abandoned

**Clinical trial abandoned with no possibility of restarting after pandemic

Optional Variables

	Year	March	April	May	June
Acute leukemias newly diagnosed	2019				
	2020				
Chronic leukemias newly diagnosed	2019				
	2020				
Lymphomas newly diagnosed	2019				
	2020				
Myelomas newly diagnosed	2019				
	2020				

Questionnaire of health impact of coronavirus on the care of cancer patients in the Medical Oncology Department

Implementation of Specific Action Plan

Date of first test	____/____/____
Triage: Clean and dirty circuits	Yes / No
On-site PCR (Suspected cases)	Yes / No Date ____/____/____
Change from in-person to telephone visit	Yes / No
In-person care maintained in department?	Yes / No

Specific treatment guidelines

Department	Yes / No
National guidelines	Yes / No
International guidelines	Yes / No
Other	Yes / No

COVID-positive patients in department

Total patients	_____
Confirmed patients	_____
Admitted patients	_____
Patient deaths	_____

Number of tests performed

PCR	_____
Serology	_____

Consultations

		Year	March	April	May	June
New consultations		2019				
		2020				
Successive consultations	Telephone	2019				
		2020				
	In-person	2019				
		2020				

Systemic treatments

	Year	March	April	May	June
Patients treated in day hospital	2019				
	2020				
Treatments in Medical oncology department	2019				
	2020				
Maintenance treatments	2019				
	2020				
Patients treated with chemotherapy	2019				
	2020				
Patients with Immunotherapy	2019				
	2020				
Patients with TKIs	2019				
	2020				
Patients with G-CSF	2019				
	2020				

Clinical research (Clinical trials)

	Year	March	April	May	June
Clinical trials recruiting	2019				
	2020				
Interrupted due to COVID-19*	2020				
Abandoned due to COVID-19**	2020				
Patients in screening	2019				
	2020				
Patients included	2019				
	2020				

*Clinical trial postponed for a time but not abandoned

**Clinical trial abandoned with no possibility of restarting after pandemic

Questionnaire of health impact of coronavirus on the care of cancer patients in the Pathology Department

Number of cytologies and biopsies

	Year	March	April	May	June
Total number of Cytologic evaluations	2019				
	2020				
Total number of Biopsies	2019				
	2020				
Number of Cytologic evaluations with diagnosis of cancer	2019				
	2020				
Number of Biopsies with diagnosis of cancer	2019				
	2020				

Optional variables

Circle most relevant answer

In how many patients have modifications been made to the therapeutic strategy due to the COVID-19 pandemic?

0% 0- 25% 25- 50% 50- 100% Not available

In how many patients has the start of radiotherapy been delayed?

0% 0- 25% 25- 50% 50- 100% Not available

How many patients have declined to start/continue radiotherapy?

0% 0- 25% 25- 50% 50- 100% Not available

Questionnaire of the health impact of coronavirus on the care of cancer patients in the Radiation Oncology Department

Implementation of Specific Action Plan

Date of first test	____/____/____
Triage: Clean and dirty circuits	Yes / No
On-site PCR (Suspected cases)	Yes / No Date ____/____/____
Change from in-person to telephone visit	Yes / No
In-person care maintained in department?	Yes / No

Specific treatment guidelines

Department	Yes / No
National guidelines	Yes / No
International guidelines	Yes / No
Other	Yes / No

COVID-positive patients in department

Total patients	_____
Confirmed patients	_____
Admitted patients	_____
Patient deaths	_____

Number of tests performed

PCR	_____
Serology	_____

Consultations

		Year	March	April	May	June
New consultations		2019				
		2020				
Successive consultations	Telephone	2019				
		2020				
	In-person	2019				
		2020				

Radiotherapy treatments

		Year	March	April	May	June
Patients treated		2019				
		2020				
Treatments performed		2019				
		2020				

Clinical research (Clinical trials)

		Year	March	April	May	June
Clinical trials recruiting		2019				
		2020				
Interrupted due to COVID-19*		2020				
Abandoned due to COVID-19**		2020				
Patients in screening		2019				
		2020				
Patients included		2019				
		2020				

*Clinical trial postponed for a time but not abandoned

**Clinical trial abandoned with no possibility of restarting after pandemic

Optional variables

Circle most relevant answer

In how many patients have modifications been made to the therapeutic strategy due to the COVID-19 pandemic?

0% 0- 25% 25- 50% 50- 100% Not available

In how many patients has the start of radiotherapy been delayed?

0% 0- 25% 25- 50% 50- 100% Not available

How many patients have declined to start/continue radiotherapy?

0% 0- 25% 25- 50% 50- 100% Not available

List of hospitals providing data from each department

N	Center	Autonomous Community	Department			
			Hematology	Medical Oncology	Radiation Oncology	Pathology
1	Virgen del Rocío University Hospital	Andalusia				X
2	Virgen de las Nieves University Hospital	Andalusia			X	X
3	Reina Sofía University Hospital	Andalusia			X	X
4	Miguel Servet University Hospital	Aragon		X		X
5	Asturias Central University Hospital	Asturias	X	X	X	X
6	Son Espases University Hospital	Balearic Islands		X	X	X
7	Gran Canaria Dr. Negrín University Hospital	Canary Islands	X		X	X
8	Nuestra Señora de Candelaria University Hospital	Canary Islands			X	X
9	Marqués de Valdecilla University Hospital	Cantabria		X		X
10	León University Hospital	Castile-Leon		X		X
11	Salamanca University Hospital	Castile-Leon	X			X
12	Guadalajara University Hospital	Castile-La Mancha	X			
13	Virgen de la salud Hospital	Castile-La Mancha	X			X
14	Vall D'Hebrón University Hospital	Catalonia	X	X	X	X
15	Santa Creu i Sant Pau Hospital	Catalonia			X	X
16	Barcelona Clinical Hospital	Catalonia			X	X
17	Bellvitge University Hospital	Catalonia			X	X
18	Parc Taulí University Hospital	Catalonia				X
19	Arnau de Vilanova University Hospital	Catalonia			X	X
20	Valencia University	Community of Valencia		X	X	X

	Clinical Hospital					
21	Elche General University Hospital	Community of Valencia	X			X
22	Santiago University Clinical Hospital	Galicia			X	
23	A Coruña University Hospital	Galicia				X
24	Ramón y Cajal University Hospital	Community of Madrid		X	X	X
25	12 de Octubre University Hospital	Community of Madrid	X		X	X
26	San Carlos Clinical Hospital	Community of Madrid	X	X		X
27	Gregorio Marañón General University Hospital	Community of Madrid				X
28	La Paz University Hospital	Community of Madrid				X
29	La Princesa University Hospital	Community of Madrid	X	X		X
30	Severo Ochoa University Hospital	Community of Madrid	X	X		X
31	Príncipe de Asturias University Hospital	Community of Madrid				X
32	Virgen de la Arrixaca University Clinical Hospital	Murcia		X		X
33	Navarra Hospital Complex	Navarra	X	X	X	X
34	Araba University Hospital	Basque country			X	X
35	Donostia University Hospital	Basque country			X	X
36	Basurto University Hospital	Basque country			X	X
Total			12	13	19	34

* Badajoz University Hospital (Extremadura) was invited to participate in the study, but did not include data from departments.

List of participating researchers in Departments

Dr. Enrique de Álava Casado (Department of Pathology, Virgen del Rocío University Hospital, Seville); Dr. José Expósito (Department of Radiation Oncology, Virgen de las Nieves University Hospital, Granada); Dr. Raimundo García del Moral (UPIGAP, Provincial Unit Intercentres of Pathological Anatomy, Granada); Dr. Amalia Palacios (Department of Radiation Oncology, Reina Sofía University Hospital, Córdoba); Dr. Rosa Ortega Salas (Department of Pathology, Reina Sofía University Hospital, Córdoba); Dr. Antonio Antón Torres (Department of Medical Oncology, Miguel Servet University Hospital, Zaragoza); Dr. Ramiro Álvarez Alegret (Department of Pathology, Miguel Servet University Hospital, Zaragoza); Dr. José María García Gala (Department of Hematology, Asturias Central University Hospital, Oviedo); Dr. Emilio Esteban González (Department of Medical Oncology, Asturias Central University Hospital, Oviedo); Dr. Germán Juan Rijo (Department of Radiation Oncology, Asturias Central University Hospital, Oviedo); Dr. Jose Ramón Riera Velasco (Department of Pathology, Asturias Central University Hospital, Oviedo); Dr. Josefa Terrasa Pons (Department of Medical Oncology, Son Espases University Hospital, Palma de Mallorca); Dr. José Pardo (Department of Radiation Oncology, Son Espases University Hospital, Palma de Mallorca); Dr. Gabriel Matheu Capo (Department of Pathology, Son Espases University Hospital, Palma de Mallorca); Dr. María Teresa Gómez Casares (Department of Hematology, Gran Canaria Dr. Negrín University Hospital, Las Palmas); Dr. Marta Lloret (Department of Radiation Oncology, Gran Canaria Dr. Negrín University Hospital, Las Palmas); Dr. Miguel Ángel Limeres Gonzáles (Department of Pathology, Gran Canaria Dr. Negrín University Hospital, Las Palmas); Dr. Claudio Fuentes (Department of Radiation Oncology, Nuestra Señora de Candelaria University Hospital, Santa Cruz de Tenerife); Dr. Maria del Carmen Maeso Fortunny (Department of Pathology, Nuestra Señora de Candelaria University Hospital, Santa Cruz de Tenerife); Dr. Fernando Rivera Herrero (Department of Medical Oncology, Marqués de Valdecilla University Hospital, Santander); Dr. Jose Javier Gómez Román (Department of Pathology, Marqués de Valdecilla University Hospital, Santander); Dr. Andrés García Palomo (Department of Medical

Oncology, León University Hospital, León); Dr. Jose Santos Santos Valien (Department of Pathology, León University Hospital, León); Dr. Marcos González Díaz (Department of Hematology, Salamanca University Hospital, Salamanca); Dr. Dolores Ludeña de la Cruz (Department of Pathology, Salamanca University Hospital, Salamanca); Dr. Dunia de Miguel Llorente (Department of Hematology, Guadalajara University Hospital, Guadalajara); Dr. Jorge Cuesta Tovar (Department of Hematology, Virgen de la salud Hospital, Toledo); Dr. Manuela Mollejo Villanueva (Department of Pathology, Virgen de la salud Hospital, Toledo); Dr. Francesc Bosch Albareda (Department of Hematology, Vall D'Hebrón University Hospital, Barcelona); Dr. José María Taberero Caturla (Department of Medical Oncology, Vall D'Hebrón University Hospital, Barcelona); Dr. Jordi Giralt (Department of Radiation Oncology, Vall D'Hebrón University Hospital, Barcelona); Dr. Santiago Ramón y Cajal Agueras (Department of Pathology, Vall D'Hebrón University Hospital, Barcelona); Dr. Gemma Sancho (Department of Radiation Oncology, Santa Creu i Sant Pau Hospital, Barcelona); Dr. Enrique Lerma Puertas (Department of Pathology, Santa Creu i Sant Pau Hospital, Barcelona); Dr. Meritxell Molla (Department of Radiation Oncology, Barcelona Clinical Hospital, Barcelona); Dr. Antonio Martínez Pozo (Department of Pathology, Barcelona, Barcelona Clinical Hospital); Dr. Ferran Guedea (Department of Radiation Oncology, Bellvitge, Barcelona University Hospital); Dr. Xavier Matias-Guiu (Department of Pathology, Bellvitge University Hospital, Barcelona, and Arnau de Vilanova University Hospital; Lleida); Dr. Joan Carles Ferreres Piñas (Department of Pathology, Parc Taulí University Hospital, Barcelona); Dr. Moisés Mira (Department of Radiation Oncology, Arnau de Vilanova University Hospital; Lleida); Dr. Andrés Cervantes Ruipérez (Department of Medical Oncology, Valencia University Clinical Hospital, Valencia); Dr. Eduardo Ferrer (Department of Radiation Oncology, Valencia University Clinical Hospital, Valencia); Dr. Antonio Ferrandez Izquierdo (Department of Pathology, Valencia University Clinical Hospital, Valencia); Dr. Venancio Conesa García (Department of Hematology, Elche General University Hospital, Alicante); Dr. Encarna Andrada Becerra (Department of Pathology, Elche General University Hospital, Alicante); Dr. Antonio Gómez Caamaño (Department of Radiation

Oncology, Santiago University Clinical Hospital, A Coruña); Dr. Ángel Concha López (Department of Pathology, A Coruña University Hospital, A Coruña); Dr. Alfredo Carrato Mena (Department of Medical Oncology, Ramón y Cajal University Hospital, Madrid); Dr. Sonsoles Sancho (Department of Radiation Oncology, Ramón y Cajal University Hospital, Madrid); Dr. Jose Palacios Calvo (Department of Pathology, Ramón y Cajal University Hospital, Madrid); Dr. Joaquín Martínez López (Department of Hematology, 12 de Octubre University Hospital, Madrid); Dr. José Pérez Regadera (Department of Radiation Oncology, 12 de Octubre University Hospital, Madrid); Dr. Jose Luis Rodríguez Peralto (Department of Pathology, 12 de Octubre University Hospital, Madrid); Dr. Celina Benavente Cuesta (Department of Hematology, San Carlos Clinical Hospital, Madrid); Dr. Pedro Pérez Segura (Department of Medical Oncology, San Carlos Clinical Hospital, Madrid); Dr. Luis Ortega Medina (Department of Pathology, San Carlos Clinical Hospital, Madrid); Dr. Maria Jesús Fernández Aceñero (Department of Pathology, Gregorio Marañón General University Hospital, Madrid); Dr. David Hardisson Hernaez (Department of Pathology, La Paz University Hospital, Madrid); Dr. Adrián Alegre Amor (Department of Hematology, La Princesa University Hospital, Madrid); Dr. Ramon Colomer i Bosch (Department of Medical Oncology, La Princesa University Hospital, Madrid); Dr. Javier Fraga Fernández (Department of Pathology, La Princesa University Hospital, Madrid); Dr. Pedro Sánchez Godoy (Department of Hematology, Severo Ochoa University Hospital, Madrid); Dr. Ana López Martín (Department of Medical Oncology, Severo Ochoa University Hospital, Madrid); Dr. Montserrat Chao Crecente (Department of Pathology, Severo Ochoa University Hospital, Madrid); Dr. Pilar Martínez Onsurbe (Department of Pathology, Príncipe de Asturias University Hospital, Madrid); Dr. José Luis Alonso Romero (Department of Medical Oncology, Virgen de la Arrixaca University Clinical Hospital, Murcia); Dr. Gabriel Matheu Capo (Department of Pathology, Virgen de la Arrixaca University Clinical Hospital, Murcia); Dr. Ana Margarita Redondo Izal (Department of Hematology, Navarra Hospital Complex, Pamplona); Dr. Ruth Vera García (Department of Medical Oncology, Navarra Hospital Complex, Pamplona); Dr. Enrique Martínez (Department of Radiation Oncology, Navarra Hospital Complex, Pamplona); Dr. Alicia Cordoba

Iturriagagoitia (Department of Pathology, Navarra Hospital Complex, Pamplona); Dr. Raúl Poza (Department of Radiation Oncology, Araba University Hospital, Araba); Dr. Isabel Guerra Merino (Department of Pathology, Araba University Hospital, Araba); Dr. José María Urraca (Department of Radiation Oncology, Donostia University Hospital, Gipuzkoa); Dr. Irune Ruiz Díaz (Department of Pathology, Donostia University Hospital, San Sebastián); Dr. Francisco Fuertes (Department of Radiation Oncology, Basurto University Hospital, Bilbao); and Dr. Maria del Carmen Etxezarraga Zuluaga (Department of Pathology, Basurto University Hospital, Bilbao).